148 results about "Ischemic stroke" patented technology

The invention discloses a nasal delivery multistage targeting bionic nano drug delivery system as well as a preparation method and application of the nasal delivery multistage targeting bionic nano drug delivery system. According to the drug delivery system, a black phosphorus nanosheet with an active oxygen scavenging effect is used as an inner core carrier, a neuroprotective agent fingolimod hydrochloride FTY720 and polydimethyldiguanide PolyMet are loaded, and a microcolloid cell membrane and a mitochondrial membrane are modified on the surface of the preparation; the nano drug delivery system is applied to treatment of cerebral arterial thrombosis reperfusion injury, can overcome the blood brain barrier, can quickly enter the brain through nasal administration, realizes efficient delivery of drugs, remarkably reduces the cerebral infarction area, reduces the brain inflammation level, protects nerve cells, greatly relieves cerebral arterial thrombosis reperfusion injury, and has application prospects.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The invention discloses application of eugenin in preparation of a medicine for treating cerebral arterial thrombosis, and belongs to the technical field of medicines. An in-vivo middle cerebral artery occlusion model is adopted, after reperfusion is conducted for 24 h, the cerebral infarction volume and movement coordination function defect of a mouse are detected to evaluate the treatment effect of eugenin, and activation of microglial cells and survival of neuronal cells are observed through immunofluorescence to clarify the action way of eugenin. Pharmacological activity shows that eugenin can obviously reduce the cerebral infarction volume of a model mouse, improve pathological damage of cells and promote recovery of a motion coordination function, and the action way of eugenin is to promote survival of neuronal cells and inhibit activation of microglial cells. Research results indicate that eugenin has the effect of resisting cerebral arterial thrombosis and can be used as a candidate medicine for developing the cerebral arterial thrombosis resisting medicine.

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention relates to a structural network-genetic map biological network model for predicting ischemic stroke and a construction method thereof, and the method comprises the steps: extracting and calculating seven multi-scale morphological features and pairwise Pearson correlation coefficients among the features from T1 weighted imaging data and diffusion tensor imaging data; constructing a 308 * 308 morphological similarity network matrix and a brain network module for identifying ischemic stroke neural dysfunction; 1782 sampling points are extracted from the Airy human brain map, and each sampling point comprises expression data of 10185 genes; the method comprises the following steps: mapping space coordinates of AHBA sampling points to a cortex package of a Desikan-Killiany map, carrying out normalization processing to output 308 * 10185 brain region gene-by-gene expression matrixes, and constructing a structural network-gene map biological network model for predicting ischemic stroke by adopting a partial least square regression method and a bootstrap method. Compared with the prior art, the model determines the specific molecular mechanism related to the phenotypic structure change of ischemic stroke injury, and the stroke occurrence probability is predicted according to the specific molecular mechanism.

The present application relates to a kind of hyperbranched polymer, nano preparation and its preparation method and application, belong to functional medical material and nanotechnology field.The hyperbranched polymer of the present application can be broken in ROS environment Release dihydrolipoic acid, play the role of antioxidant, be reduced to lipoic acid in vivo, and then play its role as coenzyme, participate in mitochondrial tricarboxylic acid cycle, restore mitochondrial function, thereby play the role of antioxidant and play the role of treating ischemic stroke.The nano preparation provided by the present application can be quickly distributed to brain in a short time, temporarily increase the paracellular permeability of BBB by inhibiting the expression of multi-drug resistance protein P-gp and ATP-dependent drug efflux protein on BBB, and the process of opening BBB by borneol is physiological and reversible, without destroying the structural integrity of blood-brain barrier.

The application relates to an IL-10 high-expression mesenchymal stem cell secretion component, a preparation method thereof and application thereof in prevention and treatment of ischemic cerebral stroke, and belongs to the technical field of cerebral stroke treatment. In order to solve the problems existing in the current stem cell clinical medication and administration method for ischemic cerebral stroke, the application provides a specially treated mesenchymal stem cell secretion component (hMSC-M), the secretion component is an IL-10 high-expression stem cell secretion component obtained by using a basic culture medium containing human IFN-gamma protein and TNF-alpha simulation peptide to induce human mesenchymal cells after expansion, and then harvesting culture and repeatedly freezing and thawing. The application finds that the hMSC-M has a significant effect on prevention and treatment of ischemic cerebral stroke through animal experiments, thereby opening up a new drug use for stem cell application, laying a foundation for developing high-efficiency related drugs for preventing and treating ischemic cerebral stroke injury, and providing a new application scheme and thought.

The invention describes catheter systems and methods for accessing the brain during endovascular / neurointervention procedures in the treatment of ischemic stroke. More specifically, a multi-axial catheter system and kit is described that improves the process of accessing a carotid artery particularly in patients having a tortuous aortic arch and thereafter improves the process of gaining access to the brain to enable the insertion of aspiration and / or the deployment clot retrieval devices. In addition, methods of utilizing these systems are described.

The invention relates to a mesenchymal stem cell-nano knapsack system, preparation thereof and application of the mesenchymal stem cell-nano knapsack system in treatment of cerebral arterial thrombosis. The invention constructs an engineered mesenchymal stem cell-thrombin responsive nano knapsack for sequential targeted delivery of rtPA, antioxidant active molecules and MSCs for ischemic stroke treatment. In a sequential delivery mode, firstly, a thrombus site is targeted, the thrombin is responded to release rtPA for thrombolysis, brain blood supply is recovered, and the rtPA thrombolysis efficiency is improved. The antioxidant active molecules are entrapped on the erythrocyte membrane bionic nanoparticles, are loaded on the surfaces of the MSCs in a knapsack form, penetrate through BBB and tend to damage ischemic penumbra and release the antioxidant active molecules by means of central transport and inflammatory homing effects of the MSCs, on one hand, oxidative stress is inhibited, a microenvironment beneficial to activity maintenance is provided for the MSCs, and on the other hand, the antioxidant active molecules are released; and meanwhile, the medicine cooperates with MSCs to play a role in protecting injured nerve and blood vessel units, so that the treatment effect on cerebral arterial thrombosis is improved.

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

The application discloses application of a marker in preparation of a product for diagnosing or assisting in diagnosing ischemic cerebral stroke, the marker being CLDN7 and / or PPM1B, and it is found through verification of clinical samples that the marker has high diagnostic efficiency on ischemic cerebral stroke, can be used as a biomarker for diagnosing and differentiating ischemic cerebral stroke, and has the advantages of high accuracy, good specificity, high sensitivity and the like, provides a brand-new thought and strategy for early diagnosis of ischemic cerebral stroke in the field, and has good clinical application value.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a PSD-95 PDZ2 peptidomimetic inhibitor and application thereof. A series of compounds are designed and synthesized by taking a tetrapeptide ETAV as a template, a structure-activity relationship of the compounds with PSD-95 PDZ2 is systematically studied, and an optimal compound 32-2, i.e., the PSD-95 PDZ2 peptidomimetic inhibitor, is screened, a structural formula of which is shown as formula (I), the PSD-95 PDZ2 peptidomimetic inhibitor has very excellent plasma stability, and exhibits significant neuroprotective activity in in-vivo and in-vitro biological activity evaluation, significantly reduces cerebral infarction caused by cerebral ischemia-reperfusion injury, and can be used for preparing a drug for treating ischemic stroke. (I).

This invention discloses the application of substances that inhibit Trx1 nitration in the preparation of drugs for treating Trx1 nitration-related diseases. This invention reveals for the first time that nitration modification of tyrosine residue 49 (Y49) of the Trx1 protein is a key pathological step in diseases such as ischemic stroke and myocardial ischemia-reperfusion injury. Inhibiting nitration at this site can effectively restore Trx1 reductase activity, enhance the binding of Trx1 to ASK1, and block the downstream ASK1-p38 / JNK apoptosis signaling pathway, thereby exerting a therapeutic effect. This invention provides a novel treatment strategy for Trx1 nitration-related diseases.

The invention discloses a biomarker combination for auxiliary diagnosis of lung adenocarcinoma and risk early warning of lung adenocarcinoma complicated with ischemic stroke and application of the biomarker combination. The biomarker combination comprises an SLC25A39 gene, an NME4 gene, an LDHA gene and an SLC7A5 gene. Reagents for detecting the expression levels of the SLC25A39 gene, the NME4 gene, the LDHA gene and the SLC7A5 gene in the biomarker combination can be applied to preparation of products for auxiliary diagnosis of the lung adenocarcinoma and risk early warning of the lung adenocarcinoma complicated with ischemic stroke, and the effect of one-detection dual-energy is achieved.

The invention belongs to the technical field of cell culture, and discloses a cell culture device for an experiment for treating cerebral ischemia stroke based on long non-coding RNA, the cell culture device comprises an incubator, a cross-shaped partition plate is fixedly connected in the incubator, a culture mechanism is arranged in the incubator, the culture mechanism comprises four stabilizing assemblies and a temperature control assembly, and the temperature control assembly is connected with the cross-shaped partition plate. The stabilizing assembly and the temperature control assembly are matched for use, the stabilizing assembly comprises sliding rails, the sliding rails are fixedly connected to the interior of the incubator, and sliding blocks are symmetrically and slidably connected to the interiors of the two sliding rails. By arranging the culture mechanism, stable, independent and environment-controllable parallel culture is carried out on a plurality of experimental samples in the same culture box, the culture dish can be stably clamped and fixed to prevent accidental overturning, and the culture dish has the partitioned independent temperature control capability; therefore, stable, reliable and flexible hardware support is provided for related frontier biomedical research.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

This invention, based on the screening and identification of environmental exocomics and metabolomics biomarkers associated with ischemic stroke, discloses an ischemic stroke risk assessment model and model construction method that integrates environmental exocomics and metabolomics biomarkers, improving the comprehensiveness, accuracy, and convenience of prediction. This invention systematically evaluates the association between exposure to mixed organic pollutants and the risk of ischemic stroke, identifying key pollutants; quantifies the impact of pollutant mixtures on the systemic metabolic network and stroke risk, revealing the mediating role of metabolic pathway disorders in pollutant-induced stroke risk; explores the potential of incorporating pollutant exposure information into clinical prediction models to improve the efficacy of ischemic stroke risk stratification, ultimately providing systematic multi-omics evidence for the causal relationship between environmental pollution and ischemic stroke, and offering new technical tools for precision disease prevention.

Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.

The invention discloses an application of a Ptbp2 accelerant in treatment of cerebral arterial thrombosis. It is found for the first time that overexpressed Ptbp2 can remarkably improve the neurological function of a mouse with the cerebral arterial thrombosis, reduce the infarct volume and relieve neuroinflammation mediated by microglia, and the overexpressed Ptbp2 can be used for effective treatment of the cerebral arterial thrombosis. The invention provides a theoretical basis for research and development of drugs for treating cerebral arterial thrombosis, opens up the application of the Ptbp2 accelerant, provides a brand new method for treating cerebral arterial thrombosis, and has a wide application prospect in the technical field of cerebral arterial thrombosis treatment.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

The object of this invention is to provide a new method for detecting stroke. [Solution] The problem is solved by a method for detecting ischemic stroke, which includes the step of obtaining a measurement value of peroxiredoxin in a blood sample taken from a subject, and which suggests that the subject has an ischemic stroke when the measurement value is higher than a predetermined reference value.

The application discloses an apparatus and a storage medium for ischemic stroke prognosis prediction. The apparatus comprises a processor and a memory, and the apparatus implements the following operations: performing image feature extraction and spatial feature extraction on a first cranial image respectively to obtain first image features and first spatial features; performing image feature extraction and spatial feature extraction on a second cranial image respectively to obtain second image features and second spatial features; performing fusion operations on the first image features and the first spatial features, the second image features and the second spatial features respectively to obtain corresponding first fusion features and second fusion features; and performing ischemic stroke prognosis prediction based on a splicing result of the first fusion features and the second fusion features to obtain a prediction result. The scheme of the application can efficiently fuse multi-modal information, improve spatial structure perception capability, and improve prediction accuracy.

The invention discloses an application of circWHSC1 as a biomarker in preparation of a product for diagnosing or treating ineffective recanalization after ischemic stroke. According to the present invention, the circRNA sequencing results show that the expression of the circWHSC1 (including hsacirc0001388 and nucirc0001336) in the ineffective recanalization patient body is significantly reduced, and the circWHSC1 is verified in the mouse brain tissue, the plasma and the thrombus model of the tMCAO model; functional studies show that the circWHSC1 can significantly reduce the cerebral infarction volume of the mouse. The circWHSC1 can be used for early diagnosis, risk assessment, severity judgment, curative effect monitoring and prognosis judgment of invalid recanalization, and can be used as a drug target for screening candidate drugs for preventing or treating invalid recanalization. The invention provides a molecular diagnosis marker and a therapeutic target for invalid recanalization, and has important clinical value.

The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating cerebral arterial thrombosis and a preparation method thereof. The traditional Chinese medicine composition comprises leeches, earthworms, miscanthus, pseudo-ginseng, astragalus membranaceus, poria cocos, almonds, peach kernels, angelica sinensis, immature bitter orange, radix polygoni multiflori preparata, pericarpium citri reticulatae, carthamus tinctorius, liquorice and borneol flakes. By combining the traditional Chinese medicines, the traditional Chinese medicine composition has a remarkable treatment effect on preventing and treating cerebral arterial thrombosis. In addition, the traditional Chinese medicine composition disclosed by the invention is high in safety and definite in curative effect, and has a wide application prospect in the field of prevention and treatment of cerebral arterial thrombosis.

This invention relates to the field of natural language processing technology, specifically to a triage method and system for neurological diseases, comprising the following steps: segmenting the syntactic structure of the patient's chief complaint text sequence and identifying nodes; calculating and quantifying the nesting degree of the patient's linguistic organization logic; and obtaining a syntactic potential depth value. This invention can filter out noise interference from complex clinical expressions and extract neurological syndrome features by comparing them with a preset internal capsule lesion pattern. By jointly analyzing feature tensors pointing to limb paralysis with syntactic potential depth values ​​below the normal threshold, dual cross-validation of somatic motor disorders and central cognitive impairment is achieved. Furthermore, by comparing with feature thresholds of peripheral nerve or spinal cord lesions, the specificity of identifying central acute and severe illnesses such as ischemic stroke is improved, optimizing the accuracy of emergency triage.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The application discloses a method, device and storage medium for training an identification model for identifying ischemic stroke. The method comprises: acquiring diffusion weighted imaging; preprocessing the diffusion weighted imaging to obtain preprocessed diffusion weighted imaging; inputting the preprocessed diffusion weighted imaging into a first model and a second model respectively, extracting corresponding image features via an encoder in the first model and the second model; performing a segmentation task and a scoring task via a decoder in the first model and the second model based on the corresponding image features, and calculating a supervised loss with labels and an unsupervised loss without labels; and determining a total loss according to the supervised loss and the unsupervised loss to train the identification model for identifying ischemic stroke. The application can improve the accuracy of the identification model in identifying ischemic stroke, reduce the difficulty of labeling, and improve the performance of the identification model in identifying ischemic stroke under the condition of scarce samples.